‘Pool and split’ high-throughput experimentation: Turning complex designs into simple assays

High-throughput experimentation (HTE) protocols enable scientists to perform multiple experiments and test multiple hypotheses, in parallel and with minimal consumption of resources and materials. Dr Marco Santagostino from the Chemical Process Development Department at Boehringer Ingelheim Pharma, Germany and his collaborators Philipp Kollmus and Raphael Steimbach devised a new protocol that greatly reduces the number of experiments needed in HTE. […]

Read More…

The trials and tribulations in the drug discovery cycle: A particular case for Alzheimer’s disease

The trials and tribulations in the drug discovery cycle

As people live longer lives, the spectre of Alzheimer’s disease will only grow. Scientists now know that the amyloid beta (Aβ) peptides are important for treating Alzheimer’s, particularly Aβ42 which aggregates into the amyloid plaques that trigger the disease. Researchers have been looking to target γ-secretase – the enzyme that creates pathogenic Aβ42 affecting the relative abundance of short Aβ […]

Read More…

NMR2: A highly accurate approach to protein-ligand binding

A novel method to determine accurately and efficiently the structure of the receptor binding sites in protein-ligand complexes promises to revolutionize drug discovery. Dr Julien Orts and his collaborators at the Swiss Federal Institute of Technology are developing a powerful and general technique, based on liquid nuclear magnetic resonance (NMR), to shed light on the details of how proteins interact […]

Read More…

Extending the half‑life of therapeutic peptides

This article is about Dr Alhamadsheh’s research which combines synthetic organic chemistry with biochemistry and molecular biology to study protein-protein interactions.

Dr Mamoun Alhamadsheh is Associate Professor at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Sciences, California. He heads a multi-disciplinary team working in the field of protein-protein interactions. Their research is focused on the development of new treatments for diseases caused by protein aggregation, including Alzheimer’s disease and transthyretin amyloidosis. Their current work in […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION